KRAS and lung cancer: In contrast, the anti-tumor effect of PBZ was not stronger than that of six other benzimidazoles tested, in the Z-score analysis for growth inhibition of KRAS-mutant and wild-type lung cancer cell lines, upon screening of 1271 compounds, where it was identified as one of 50 top-ranking compounds [39].